Recherches "plusieurs pathologies" RAGNAR (42756493CAN2002) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene;Alterations Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides CA045-020 (PIVOT IO 020) Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children,;Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Paris FRANCOIS DOZ
Gynécologie - Ovaires AGO-OVAR 2.29 Atezolizumab in combination with Bevacizumab and Chemotherapy;versus Bevacizumab and Chemotherapy;in recurrent ovarian cancer À a randomized Phase III trial;An ENGOT Trial Paris MANUEL RODRIGUES
Gynécologie - Ovaires RAMP-201 (VS-6766-201 / ENGOT-ov60) A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Paris MANUEL RODRIGUES
Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Pédiatrie Tumeurs solides I3Y-MC-JPCS JPCS(2.1) Clinical Protocol Addendum Page 1;LY2835219;1. Protocol Addendum I3Y-MC-JPCS(2.1);A Phase 1b Dose Escalation Study of Abemaciclib in;Combination with Temozolomide and Irinotecan (Part A);and Abemaciclib in Combination with Temozolomide;(Part B) in Pediatric and Young Adult Patients with;Relapsed/Refractory Solid Tumors Paris ISABELLE AERTS
Recherches "plusieurs pathologies" REGOMUNE A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Saint-Cloud SEGOLENE HESCOT
Sein métastatique RH+ SERENA-6 D8534C00001 A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN
Recherches "plusieurs pathologies" MOST Plus My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors Paris CHRISTOPHE LE TOURNEAU